ProShare Advisors LLC Sells 294 Shares of Medpace Holdings, Inc. $MEDP

ProShare Advisors LLC decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,188 shares of the company’s stock after selling 294 shares during the period. ProShare Advisors LLC’s holdings in Medpace were worth $687,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of MEDP. King Luther Capital Management Corp boosted its position in shares of Medpace by 1.5% during the second quarter. King Luther Capital Management Corp now owns 20,861 shares of the company’s stock valued at $6,547,000 after buying an additional 311 shares during the last quarter. Roberts Glore & Co. Inc. IL raised its position in Medpace by 3.3% in the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 4,391 shares of the company’s stock worth $1,378,000 after buying an additional 140 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Medpace during the 2nd quarter valued at about $1,059,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Medpace by 83.5% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 158,852 shares of the company’s stock valued at $49,857,000 after acquiring an additional 72,286 shares during the last quarter. Finally, Aviva PLC boosted its holdings in shares of Medpace by 58.5% during the 2nd quarter. Aviva PLC now owns 2,883 shares of the company’s stock valued at $905,000 after acquiring an additional 1,064 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.8%

MEDP opened at $590.18 on Wednesday. The firm’s 50 day simple moving average is $543.35 and its two-hundred day simple moving average is $428.47. The company has a market capitalization of $16.62 billion, a PE ratio of 41.27, a PEG ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $625.00.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. During the same period in the prior year, the business posted $3.01 EPS. Medpace’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a report on Monday, October 27th. BMO Capital Markets started coverage on shares of Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 target price for the company. Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and increased their price target for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Barclays raised their price target on Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a research note on Friday, October 24th. Finally, UBS Group cut Medpace from a “neutral” rating to a “sell” rating and upped their price objective for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $487.18.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 18,000 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $605.00, for a total value of $10,890,000.00. Following the completion of the sale, the vice president owned 47,500 shares in the company, valued at $28,737,500. This represents a 27.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 6,047 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $591.00, for a total value of $3,573,777.00. Following the transaction, the chief executive officer owned 893,368 shares of the company’s stock, valued at approximately $527,980,488. This trade represents a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 170,255 shares of company stock valued at $96,157,774 in the last ninety days. 20.30% of the stock is currently owned by company insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.